Similar articles

• [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].

  Dalmases A, Rojo F, Rovira A, Albanell J. Dalmases A, et al. Med Clin (Barc). 2013 Aug 17;141(4):176-80. doi: 10.1016/j.medcli.2013.04.008. Epub 2013 Jun 27. Med Clin (Barc). 2013. PMID: 23809407 Review. Spanish. No abstract available.
• Update on HER-kinase-directed therapy in prostate cancer.

  Gross ME, Jo S, Agus DB. Gross ME, et al. Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Clin Adv Hematol Oncol. 2004. PMID: 16163160 Review.
• New oncology strategy: molecular targeting of cancer cells.

  Capriotti T. Capriotti T. Medsurg Nurs. 2004 Jun;13(3):191-5. Medsurg Nurs. 2004. PMID: 15219169 Review. No abstract available.
• HER-2-positive breast cancer: hope beyond trastuzumab.

  Bartsch R, Wenzel C, Zielinski CC, Steger GG. Bartsch R, et al. BioDrugs. 2007;21(2):69-77. doi: 10.2165/00063030-200721020-00001. BioDrugs. 2007. PMID: 17402790 Review.
• HER2 targeted therapy in breast cancer...beyond Herceptin.

  Pal SK, Pegram M. Pal SK, et al. Rev Endocr Metab Disord. 2007 Sep;8(3):269-77. doi: 10.1007/s11154-007-9040-6. Rev Endocr Metab Disord. 2007. PMID: 17899385 Review.